

Ann Marie Navar-Boggan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5362070/publications.pdf>

Version: 2024-02-01

139
papers

5,628
citations

126858

33
h-index

91828

69
g-index

144
all docs

144
docs citations

144
times ranked

8063
citing authors

#	ARTICLE	IF	CITATIONS
1	Application of New Cholesterol Guidelines to a Population-Based Sample. <i>New England Journal of Medicine</i> , 2014, 370, 1422-1431.	13.9	571
2	Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 198-208.	2.2	569
3	Nonmedical Exemptions to School Immunization Requirements. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1757.	3.8	337
4	Apolipoprotein B Particles and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2019, 4, 1287.	3.0	299
5	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. <i>Circulation</i> , 2015, 131, 451-458.	1.6	283
6	Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. <i>European Heart Journal</i> , 2017, 38, ehw302.	1.0	276
7	Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0149160.	1.1	170
8	Sex Differences in the Use of Statins in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005562.	0.9	155
9	Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011765.	1.6	139
10	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. <i>Circulation</i> , 2019, 139, 1603-1611.	1.6	115
11	Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research. <i>Journal of the American College of Cardiology</i> , 2019, 73, 317-335.	1.2	114
12	Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy. <i>JAMA Cardiology</i> , 2017, 2, 1217.	3.0	100
13	Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1424.	3.8	95
14	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. <i>JAMA Cardiology</i> , 2018, 3, 739.	3.0	94
15	Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100009.	1.3	90
16	Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e019636.	1.6	80
17	Research Needs to Improve Hypertension Treatment and Control in African Americans. <i>Hypertension</i> , 2016, 68, 1066-1072.	1.3	78
18	Managing Atherosclerotic Cardiovascular Risk in Young Adults. <i>Journal of the American College of Cardiology</i> , 2022, 79, 819-836.	1.2	72

#	ARTICLE	IF	CITATIONS
19	Trajectories of Non-HDL Cholesterol Across Midlife. <i>Journal of the American College of Cardiology</i> , 2019, 74, 70-79.	1.2	67
20	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1633-1639.	1.2	58
21	Use of Open Access Platforms for Clinical Trial Data. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1283.	3.8	57
22	Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. <i>PLoS ONE</i> , 2021, 16, e0251963.	1.1	56
23	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. <i>American Heart Journal</i> , 2017, 193, 84-92.	1.2	55
24	Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. <i>American Journal of Preventive Cardiology</i> , 2021, 8, 100250.	1.3	51
25	Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children. <i>Hum Vaccin</i> , 2008, 4, 286-291.	2.4	50
26	Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1563.	3.8	49
27	Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	49
28	New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1564-1575.	1.2	49
29	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. <i>JAMA Cardiology</i> , 2018, 3, 1192.	3.0	48
30	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017, 136, 1193-1203.	1.6	47
31	Evaluation of Mortality Data From the Social Security Administration Death Master File for Clinical Research. <i>JAMA Cardiology</i> , 2019, 4, 375.	3.0	43
32	Trends of blood pressure control in the U.S. during the COVID-19 pandemic. <i>American Heart Journal</i> , 2022, 247, 15-23.	1.2	40
33	Pediatric-Specific Antimicrobial Susceptibility Data and Empiric Antibiotic Selection. <i>Pediatrics</i> , 2012, 130, e615-e622.	1.0	39
34	Performance of Guideline Recommendations for Prevention of Myocardial Infarction in Young Adults. <i>Journal of the American College of Cardiology</i> , 2020, 76, 653-664.	1.2	39
35	Association of Blood Pressure Patterns in Young Adulthood With Cardiovascular Disease and Mortality in Middle Age. <i>JAMA Cardiology</i> , 2020, 5, 382.	3.0	35
36	Measuring Immunization Coverage among Preschool Children: Past, Present, and Future Opportunities. <i>Epidemiologic Reviews</i> , 2006, 28, 27-40.	1.3	34

#	ARTICLE	IF	CITATIONS
37	The Accuracy of Cardiovascular Pooled Cohort Risk Estimates in U.S. Older Adults. <i>Journal of General Internal Medicine</i> , 2020, 35, 1701-1708.	1.3	31
38	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2041.	3.8	30
39	The Evolving Story of Triglycerides and Coronary Heart Disease Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 347.	3.8	30
40	Prenatal Immunization Education. <i>American Journal of Preventive Medicine</i> , 2007, 33, 211-213.	1.6	29
41	Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment. <i>JAMA Cardiology</i> , 2016, 1, 864.	3.0	29
42	What to say and how to say it. <i>Current Opinion in Cardiology</i> , 2016, 31, 537-544.	0.8	28
43	Machine Learning-Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 844.	3.0	28
44	The Association Between Low-Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2560-2567.	1.3	26
45	Risk Prediction With Electronic Health Records. <i>JAMA Cardiology</i> , 2016, 1, 976.	3.0	25
46	Fear-Based Medical Misinformation and Disease Prevention. <i>JAMA Cardiology</i> , 2019, 4, 723.	3.0	25
47	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. <i>American Journal of Cardiology</i> , 2020, 126, 94-102.	0.7	25
48	An Approach to Improve the Negative Predictive Value and Clinical Utility of Transthoracic Echocardiography in Suspected Native Valve Infective Endocarditis. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 315-322.	1.2	24
49	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004249.	0.9	24
50	Association of Primary Care Providers' Beliefs of Statins for Primary Prevention and Statin Prescription. <i>Journal of the American Heart Association</i> , 2019, 8, e010241.	1.6	23
51	Medication Discontinuation in the IMPROVE-IT Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005041.	0.9	23
52	Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. <i>JAMA Internal Medicine</i> , 2020, 180, 1531.	2.6	23
53	Lipid Testing and Statin Dosing After Acute Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	22
54	The patient journey with proprotein convertase subtilisin/kexin type 9 inhibitors in community practice. <i>Journal of Clinical Lipidology</i> , 2019, 13, 725-734.	0.6	21

#	ARTICLE	IF	CITATIONS
55	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2015, 170, 865-871.	1.2	20
56	An Observational Study of the Association of Video- Versus Text-Based Informed Consent With Multicenter Trial Enrollment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004675.	0.9	20
57	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006548.	0.9	20
58	Simultaneous Single-Particle Tracking and Visualization of Domain Structure on Lipid Monolayers. <i>Langmuir</i> , 2003, 19, 4876-4879.	1.6	19
59	Are Recent Medical Graduates More Skeptical of Vaccines?. <i>Vaccines</i> , 2013, 1, 154-166.	2.1	19
60	Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e019331.	1.6	19
61	U.S. population at increased risk of severe illness from COVID-19. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100156.	1.3	19
62	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	2.9	19
63	The impact of race and ethnicity on outcomes in 19,584 adults hospitalized with COVID-19. <i>PLoS ONE</i> , 2021, 16, e0254809.	1.1	19
64	Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 48-55.	1.6	19
65	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018, 137, 938-947.	1.6	17
66	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2019, 214, 113-124.	1.2	17
67	Evaluating the Impact of Interruptive Alerts within a Health System: Use, Response Time, and Cumulative Time Burden. <i>Applied Clinical Informatics</i> , 2019, 10, 909-917.	0.8	17
68	Association Between Triglycerides and Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease (From the Bypass Angioplasty Revascularization) <i>Tj ETQq0 0 0 rgBT0/Overlock10 Tf 50 2</i>	1.0	17
69	Association of Clinician Knowledge and Statin Beliefs With Statin Therapy Use and Lipid Levels (A) <i>Tj ETQq1 1 0.784314 rgBT/Overlock 0.7 16</i>	1.0	17
70	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 336.	3.0	16
71	Incremental Benefits of Machine Learning—When Do We Need a Better Mousetrap?. <i>JAMA Cardiology</i> , 2021, 6, 621.	3.0	15
72	Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2018, 200, 118-124.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. <i>Journal of the American Heart Association</i> , 2020, 9, e017915.	1.6	14
74	Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. <i>JAMA Cardiology</i> , 2016, 1, 700.	3.0	13
75	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007492.	0.9	13
76	Hypertension Control Among Patients Followed by Cardiologists. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 352-357.	0.9	12
77	Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events. <i>Hypertension</i> , 2017, 70, 907-914.	1.3	12
78	Improving patient risk communication: Translating cardiovascular risk into standardized risk percentiles. <i>American Heart Journal</i> , 2018, 198, 18-24.	1.2	12
79	Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1117.	3.0	12
80	Disparities in preschool immunization coverage associated with maternal age. <i>Hum Vaccin</i> , 2009, 5, 557-561.	2.4	11
81	Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. <i>American Heart Journal</i> , 2018, 195, 151-152.	1.2	11
82	Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e013229.	1.6	11
83	Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans. <i>Journal of the American Heart Association</i> , 2021, 10, e019254.	1.6	11
84	Challenges in Interpreting the Lipid-Lowering Trials. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1549.	3.8	10
85	Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2021, 6, 92-96.	3.0	10
86	Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia. <i>European Cardiology Review</i> , 2021, 16, e54.	0.7	10
87	The feasibility and accuracy of evaluating lipid management performance metrics using an electronic health record. <i>American Heart Journal</i> , 2013, 166, 701-708.	1.2	9
88	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009251.	1.6	9
89	Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020. <i>Journal of Women's Health</i> , 2020, 29, 1091-1100.	1.5	9
90	Variability in performance measures for assessment of hypertension control. <i>American Heart Journal</i> , 2013, 165, 823-827.	1.2	8

#	ARTICLE	IF	CITATIONS
91	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. <i>American Heart Journal</i> , 2020, 225, 88-96.	1.2	8
92	Reductions in telemetry order duration do not reduce telemetry utilization. <i>Journal of Hospital Medicine</i> , 2014, 9, 795-796.	0.7	7
93	A case of spontaneous coronary artery dissection diagnosed by coronary computed tomography angiography. <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 88-89.	0.7	7
94	Electronic Health Record Data Quality Issues Are Not Remedied by Increasing Granularity of Diagnosis Codes. <i>JAMA Cardiology</i> , 2019, 4, 465.	3.0	7
95	Have the Major Cardiovascular Outcomes Trials Impacted Payer Approval Rates for PCSK9 Inhibitors?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006019.	0.9	7
96	Application of the New Cholesterol Guidelines. <i>New England Journal of Medicine</i> , 2014, 371, 77-79.	13.9	6
97	The Potential and Pitfalls of Coronary Artery Calcium Scoring. <i>JAMA Cardiology</i> , 2022, 7, 11.	3.0	6
98	Cardiovascular care for older adults: hypertension and stroke in the older adult. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 373-9.	0.2	6
99	Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 383-392.	0.9	6
100	Prevalence, treatment, and control of severe hyperlipidemia. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100079.	1.3	5
101	Prospective evaluation of lipid management following acute coronary syndrome in non-Western countries. <i>Clinical Cardiology</i> , 2021, 44, 955-962.	0.7	5
102	Underdiagnosis of familial hypercholesterolaemia: innovation is overdue. <i>European Heart Journal</i> , 2022, 43, 3255-3257.	1.0	5
103	The impact of a measurement and feedback intervention on blood pressure control in ambulatory cardiology practice. <i>American Heart Journal</i> , 2014, 167, 466-471.	1.2	4
104	Evolving Approaches for Statins in Primary Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1981.	3.8	4
105	Impediments to Implementing Guideline-Directed Medical Therapies. <i>JAMA Cardiology</i> , 2019, 4, 830.	3.0	4
106	TRIGLYCERIDES AS A RISK FACTOR FOR CORONARY HEART DISEASE: WHAT MEASURE AND WHAT CUTOFF?. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1865.	1.2	4
107	Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. <i>Journal of Clinical Lipidology</i> , 2021, 15, 832-839.	0.6	4
108	Sticky Issues for Adherence in Secondary Prevention. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1555-1557.	1.2	3

#	ARTICLE	IF	CITATIONS
109	Statins Work, but Only in People Who Take Them. JAMA Cardiology, 2019, 4, 214.	3.0	3
110	County-level phenomapping to identify disparities in cardiovascular outcomes: An unsupervised clustering analysis. American Journal of Preventive Cardiology, 2020, 4, 100118.	1.3	3
111	Is Coronary Calcium Scanning the “Secret Sauce” for Affordable Atherosclerotic Cardiovascular Disease Primary Prevention Trials?. JACC: Cardiovascular Imaging, 2021, 14, 1017-1019.	2.3	3
112	Patients Affected by Changes to Hypertension Guideline”Reply. JAMA - Journal of the American Medical Association, 2014, 312, 846.	3.8	2
113	Response to Letter Regarding Article, “Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease”: Circulation, 2015, 132, e203.	1.6	2
114	RECURRENT CARDIOVASCULAR EVENT RATES IN A CONTEMPORARY COHORT OF 829,498 ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. Journal of the American College of Cardiology, 2017, 69, 59.	1.2	2
115	Some patient interventions increased thiazide prescriptions and improved blood pressure control. Annals of Internal Medicine, 2019, 170, JC46.	2.0	2
116	High Rates of Off-label Prescribing and the Urgent Need for a Randomized Clinical Trial. JAMA Cardiology, 2020, 5, 692.	3.0	2
117	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. Clinical Cardiology, 2021, 44, 863-870.	0.7	2
118	Extrapolating Survival From Randomized Clinical Trial Data”Possibilities and Caution. JAMA Cardiology, 2021, 6, 1305.	3.0	2
119	Transforming the Paradigm for Lipid Lowering. JAMA Cardiology, 2021, , .	3.0	2
120	Chronic Stress and Risks for Myocardial Infarction in U.S. Adults. Innovation in Aging, 2020, 4, 394-395.	0.0	2
121	Communicating the Benefits of Vaccination in Light of Potential Risks. JAMA Cardiology, 2022, 7, 612.	3.0	2
122	In patients with MI, new-onset or existing AF increased risk for CV events at 90 days. Annals of Internal Medicine, 2016, 164, JC66.	2.0	1
123	Open Access Platforms for Sharing Clinical Trial Data”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 666.	3.8	1
124	The Complexities of Hypertension. JAMA Cardiology, 2017, 2, 389.	3.0	1
125	Regional Differences in Secondary Prevention Therapy”Geography Should Not Be Destiny. JAMA Cardiology, 2019, 4, 873.	3.0	1
126	Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. Journal of the American College of Cardiology, 2020, 75, 835-837.	1.2	1

#	ARTICLE	IF	CITATIONS
127	The incremental value of angiographic features for predicting recurrent cardiovascular events: Insights from the Duke Databank for Cardiovascular Disease. <i>Atherosclerosis</i> , 2021, 321, 1-7.	0.4	1
128	The Cumulative Impact of Chronic Stressors on Risks for Myocardial Infarction in U.S. Older Adults. <i>Psychosomatic Medicine</i> , 2021, Publish Ahead of Print, 987-994.	1.3	1
129	A High-Dose Continuous Haloperidol Infusion Successfully Controlled Intractable Terminal Delirium (748). <i>Journal of Pain and Symptom Management</i> , 2011, 41, 301-302.	0.6	0
130	PATIENT PERCEPTIONS AND MANAGEMENT OF CHOLESTEROL AMONG INDIVIDUALS WITH OR WITHOUT DIABETES IN COMMUNITY PRACTICE: RESULTS FROM THE PALM REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1710.	1.2	0
131	PRACTICE-LEVEL VARIATION IN STATIN USE AND LDL-C CONTROL IN THE UNITED STATES: RESULTS FROM THE PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT (PALM) REGISTRY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1706.	1.2	0
132	Questioning the Benefit of Statins for Low-Risk Populationsâ€”Medical Misinformation or Scientific Evidence?â€”Reply. <i>JAMA Cardiology</i> , 2020, 5, 233.	3.0	0
133	Choosing an Initial Therapeutic Approach for Hypertensionâ€”Time for a Fixed-Dose Combination First?. <i>JAMA Cardiology</i> , 2020, 5, 1217.	3.0	0
134	Teaching Old Treatments New Tricks. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009725.	1.4	0
135	Heroism in the Face of the COVID-19 Pandemic. <i>JAMA Cardiology</i> , 2020, 5, 1163.	3.0	0
136	Can the Absence of Hypertension Refine the Risk Assessment of Older Adults for Future Cardiovascular Events?. <i>American Journal of Cardiology</i> , 2021, 142, 83-90.	0.7	0
137	The Changing Profile of Autopsies in Cardiovascular Deaths in the United States, 2003-2018. <i>American Journal of Cardiology</i> , 2021, 140, 150-151.	0.7	0
138	Statin Eligibility Under American and European Cholesterol Guidelinesâ€”Reply. <i>JAMA Cardiology</i> , 2017, 2, 460.	3.0	0
139	Limitations of Observational Studies for Aspirin in Primary Prevention and the Need for Randomized Trials. <i>Radiology: Cardiothoracic Imaging</i> , 2022, 4, e220079.	0.9	0